Premium
A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006
Author(s) -
Sommet Agnès,
Durrieu Genevieve,
LapeyreMestre Maryse,
Montastruc JeanLouis
Publication year - 2012
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.2307
Subject(s) - pharmacovigilance , medicine , pharmacoepidemiology , heat wave , drug reaction , pediatrics , adverse drug reaction , adverse effect , drug , pharmacology , medical prescription , ecology , climate change , biology
Purpose Heat waves could reveal or aggravate several ‘serious’ adverse drug reactions (ADRs) in elderly. Thus, we wanted to describe the main characteristics of heat‐related ‘serious’ ADRs occurred in patients older than 70 years during these two events in France (2003 and 2006). Methods We analysed ‘serious’ ADRs reported to the network of French pharmacovigilance centres in summer 2003 and 2006 and suspected to be heat related. ‘Serious’ ADRs occurred during summers with heat waves (2003 and 2006) were compared with ADRs occurred during the same months in the summers of 2004 and 2005 (reference period). Results Patients' characteristics and number of ‘serious’ ADRs were similar whatever the year of the study. Number of drug‐related deaths seemed higher in 2003 than in 2004–2005. More ‘serious’ heat‐related ADRs were reported in the summers of 2003 and 2006 (68 in 2003 and 72 in 2006). Comparing with the reference period, metabolic ADRs were less frequent during the summers of 2003 (29%, p = 0.0001) and 2006 (39%, p = 0.003). Occurrence of other ADRs was similar whatever the period. Drugs more frequently involved during heat waves were diuretics, serotonic antidepressants, angiotensin converting inhibitors and proton pump inhibitors. Differences between 2003 and 2006 were found for non‐dopaminergic (atropinic) antiparkinsonians or antiepileptics (most frequently involved in 2006) and beta‐blockers or proton pump inhibitors (less frequently involved in 2006). Conclusion The present study underlines the interest of a National Pharmacovigilance Database to follow each year the role of drugs in heat‐related ADRs. This survey should be associated with other pharmacoepidemiological methods, such as case–control or population‐based studies. Copyright © 2011 John Wiley & Sons, Ltd.